BD Diagnostics and Lab 21 will collaborate on the development of oncology assays
for the BD MAX benchtop molecular system, the companies announced. Lab 21 will develop PCR-based assays on the BD MAX platform, and BD will manufacture and sell the tests worldwide. Focusing on cancer patients, the companies plan to design the first two assays to detect mutations in the KRAS and BRAF genes. The assay will be the first personalized cancer diagnostics test designed for the BD MAX system.
The collaboration includes the development of novel nucleic acid extraction procedures from formalin-fixed paraffin-embedded tissue. The companies declined to disclose the financial terms of the agreement.
“When used in conjunction with other laboratory and clinical information, these assays will provide critical input to support oncologist sand their patients in making more informed decisions about their care,” says Tom Polen, president, BD Diagnostics-Diagnostic Systems. Previously, both companies worked together to develop a molecular diagnostic assay for detecting the Aspergillus fungus
using the BD MAX platform.